Abstract: Objective To investigate the expression of carboxyl teminus of Hsc70-interacting protein （CHIP） in human breast cancer and its clinical significance. Methods Expression of CHIP was detected by the immunohistochemistry in 128 cases of breast cancer specimens. The CHIP expression in breast cancer and its relationship with clinicopathological features and molecular types were analyzed using non-parametric statistical test method. Results The positive rate of CHIP in breast cancer was 60.2%； and the positive rate in clinical stage Ⅲ-Ⅳ was 43.2%， which was significantly lower than 67.0% in stageⅠ-Ⅱ（P＜0.05）. CHIP positive expression rate in cases with lymph node metastasis was lower than that of patients without lymph node metastasis （P＜0.05）. CHIP positive expression rates of Luminal A subtype， Luminal B subtype， HER-2 subtype and Basal-like subtype patients were 66.7%， 70.5%， 50.0% and 44.0%，repectively （P＜0.05）. The level of expression of CHIP has no significant difference with age， histological grade， tumor size, distant metastasis or HER-2 status. Conclusion The expression of CHIP may relate to tumorgenesis and development， and it might be used as a predictor of recurrent risk.